2024-10-25 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

**1. Performance & Comparison:**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) with a **cumulative return of 856.19%** compared to VOO's **135.48%**. This represents a **gap of 720.71%**, placing it within the **89.53rd percentile** of historical performance against the S&P 500.

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops, manufactures, and markets pharmaceutical products, including treatments for diabetes, cancer, and autoimmune diseases.

**2. Recent Price Movement:**

* **Closing price:** 891.32
* **Post-market price:** 891.54
* **5-day moving average:** 904.93
* **20-day moving average:** 904.4
* **60-day moving average:** 906.83

The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a potential short-term downward trend.

**3. Technical Indicators & Expected Return:**

* **RSI:** 51.77 - This indicates a neutral sentiment with no strong signs of overbought or oversold conditions.
* **PPO:** -0.18 - A negative PPO value suggests that the stock's price momentum is weakening.
* **Delta_Previous_Relative_Divergence:** -2.95 (-) - This indicates a recent decline in relative divergence, suggesting a potential bearish signal.
* **Expected Return:** 96.56% - This indicates that LLY is expected to generate a significantly higher return than the S&P 500 over the long term (2 years or more) if you were to adopt a long-term, dollar-cost averaging strategy.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

Eli Lilly's recent earnings have been strong, exceeding analysts' expectations. The company's Q2 2024 earnings report, released on August 8th, showcased revenue growth driven by strong demand for key drugs such as Mounjaro and Trulicity. This momentum is anticipated to continue in the upcoming quarters.

**5. News & Recent Issues:**

**Recent Earnings News:**

* **August 8, 2024:** Eli Lilly exceeded analysts' expectations for Q2 2024, reporting strong revenue growth driven by key drugs like Mounjaro and Trulicity. The company's pipeline also continues to deliver promising results, further bolstering investor confidence.

**Recent Market Outlook:**

* **Finbold:** Eli Lilly's strong performance in recent years, particularly with the success of Mounjaro, has attracted significant investor interest. Analyst consensus suggests a positive outlook for the company, with expectations for continued growth and profitability.

**Analyst Opinions:**

* **Overall, analysts are positive on Eli Lilly's prospects, citing its robust product portfolio, promising pipeline, and strong market position.** The company's focus on innovative therapies and its commitment to research and development are key drivers of its success.

**6. Summary:**

Eli Lilly and Co (LLY) has exhibited impressive outperformance compared to the S&P 500, demonstrating its strength and growth potential. Recent earnings have been strong, exceeding expectations and showcasing a robust pipeline and promising future. While short-term technical indicators suggest potential downward pressure, the long-term outlook remains positive, supported by its strong earnings and market position.

**7. Conclusion:**

Eli Lilly and Co (LLY) presents a compelling investment opportunity for investors seeking exposure to the pharmaceutical industry. Its strong historical performance, recent earnings beat, and positive analyst consensus make it a promising stock for consideration. However, investors should keep an eye on short-term technical indicators and conduct further research before making any investment decisions. 
